TSH / T3 / T4

The Thyroid's Role in Longevity: More Than Metabolism

The thyroid gland is often described as the body's metabolic thermostat, but this understates its reach. Thyroid hormone receptors are present in virtually every cell type in the human body — heart muscle, neurons, liver cells, bone, gut epithelium, and skin. The thyroid hormones T3 and T4 regulate not just metabolic rate but mitochondrial biogenesis, protein synthesis, cholesterol metabolism, cardiac contractility, bone turnover, gut motility, and neurotransmitter production. When thyroid function is suboptimal, the effects ripple across every system.

From a longevity perspective, the thyroid matters for several reasons beyond symptom burden. Subclinical hypothyroidism — TSH elevated above the longevity-optimal range with T4 still normal — is independently associated with cardiovascular disease, elevated LDL, increased arterial stiffness, and cognitive decline. Hyperthyroidism and even high-normal thyroid function are associated with accelerated bone loss, atrial fibrillation, and increased all-cause mortality. The optimal zone is genuinely narrow, and most people are never tested with the precision required to know where they fall.

A further complexity: standard TSH testing misses a significant subset of people who convert T4 to active T3 poorly. These individuals may have perfectly normal TSH and T4 while experiencing genuine tissue-level thyroid deficiency — and will be told their thyroid is fine based on incomplete testing.

Understanding the Thyroid Hormone Cascade

To interpret thyroid labs correctly, it helps to understand how the system works. The hypothalamus releases thyrotropin-releasing hormone (TRH), which signals the pituitary gland to release TSH. TSH travels through the bloodstream to the thyroid gland, where it stimulates the production and release of thyroid hormones. The thyroid secretes approximately 80% T4 and 20% T3 directly into circulation.

T4 — the dominant secretory product — is largely inactive on its own. It functions as a prohormone: a stable, long-circulating reservoir that peripheral tissues convert to the biologically active T3. This conversion is performed by deiodinase enzymes, primarily in the liver, kidneys, and intestinal wall. The converted T3 then enters cells, binds to thyroid hormone receptors in the nucleus, and directly regulates gene transcription — altering the production of thousands of proteins involved in energy metabolism, growth, and cellular function.

This two-step process creates a critical vulnerability. TSH reflects the pituitary's assessment of thyroid hormone adequacy. But the pituitary is sensitive primarily to circulating T4 levels, not directly to T3. Someone who converts T4 to T3 poorly can have a TSH that looks perfectly normal — the pituitary is satisfied with T4 levels — while peripheral tissues are functionally T3-deficient. This is why measuring Free T3 directly is essential, not optional, in a complete thyroid assessment.

Why the Standard TSH Range Is Too Wide

The standard TSH reference range of approximately 0.5–4.5 mIU/L was established by measuring TSH in a large population and defining the central 95% as "normal." The problem with this approach is that the reference population included a significant proportion of people with undetected thyroid disease — particularly early Hashimoto's thyroiditis, which is present but asymptomatic in millions of adults. Including these individuals inflates the upper end of the range.

When studies exclude people with detectable thyroid antibodies and known thyroid disease, the TSH range narrows considerably — with most truly healthy adults falling between 0.5 and 2.5 mIU/L. The American Association of Clinical Endocrinologists proposed tightening the reference range to 0.3–3.0 mIU/L in 2002, but the change was not universally adopted.

More importantly from a longevity standpoint, the optimal range appears to be even narrower than any standard reference. A large analysis of NHANES data found that cardiovascular mortality was lowest in individuals with TSH between 1.0 and 2.0 mIU/L, with risk rising progressively above 2.5 mIU/L. The Cardiovascular Health Study similarly found that TSH above 2.5 mIU/L predicted incident heart failure and atrial fibrillation in older adults, while a UK Biobank analysis found cognitive performance best in the 1–2 mIU/L range. ¹

The practical implication: a TSH of 3.8 mIU/L reported as "normal" by a standard lab is associated with meaningfully elevated cholesterol, reduced cardiac function, cognitive slowing, and fatigue relative to a TSH of 1.5 mIU/L. Both are within range. Only one is optimal.

Hashimoto's Thyroiditis: The Hidden Epidemic

Hashimoto's thyroiditis is the most common cause of hypothyroidism in developed countries, affecting an estimated 5% of the population — and up to 15–20% of women over 60. It is an autoimmune condition in which the immune system produces antibodies against thyroid peroxidase (TPO) and thyroglobulin (TgAb), two proteins essential for thyroid hormone synthesis. Over years to decades, this immune attack progressively destroys thyroid tissue, reducing the gland's capacity to produce hormones.

The critical point for longevity medicine: Hashimoto's begins years or decades before TSH becomes abnormal. Antibodies rise first — often in the 20s or 30s — while TSH and T4 remain completely normal. During this period, many people experience fatigue, brain fog, hair loss, and mood changes that are dismissed because their labs look fine. The antibody-positive, TSH-normal stage is called "euthyroid Hashimoto's," and it is both common and commonly missed.

Testing for TPO antibodies and TgAb in addition to TSH is the only way to detect Hashimoto's before it impairs thyroid function. Early detection matters because:

• Selenium supplementation (200 mcg/day) has been shown in randomized trials to reduce TPO antibody titers by 20–40% and may slow disease progression
• Identifying Hashimoto's explains symptoms that would otherwise be unexplained and prompts appropriate monitoring
• People with Hashimoto's have higher rates of other autoimmune conditions and benefit from broader evaluation
• Dietary interventions (particularly gluten elimination in those with concurrent celiac sensitivity) may reduce antibody burden in a subset of patients

The T4-to-T3 Conversion Problem

Standard thyroid screening in most clinical settings measures only TSH — and often T4. Free T3 is ordered infrequently, typically only when overt hyperthyroidism is suspected. This is a significant gap, because a meaningful subset of people have normal TSH and T4 with suboptimal Free T3 — producing genuine hypothyroid symptoms despite labs that look normal by standard criteria.

Poor T4-to-T3 conversion is not a rare edge case. It is common enough to be a primary driver of treatment-resistant hypothyroid symptoms and unexplained fatigue in the general population. The main factors that impair conversion include:

• Selenium deficiency: Selenium is the essential cofactor for type 1 and type 2 deiodinase enzymes, which perform the T4-to-T3 conversion. Selenium deficiency is more prevalent than commonly recognized, particularly in regions with selenium-poor soils and in people eating low-meat diets.
• Iron deficiency: Iron is required for thyroid peroxidase activity in the thyroid gland itself, and iron deficiency impairs both thyroid hormone synthesis and peripheral conversion. This is one reason why low ferritin frequently accompanies thyroid dysfunction.
• Chronic stress and elevated cortisol: Cortisol inhibits deiodinase activity and shifts T4 conversion toward reverse T3 (an inactive isomer) rather than active T3. Chronically stressed individuals often have low-normal T3 with elevated reverse T3.
• Very low-carbohydrate diets: Carbohydrate restriction reduces T3 production, a documented metabolic adaptation. Active T3 falls while reverse T3 may rise — sometimes to a degree that produces symptomatic hypothyroidism despite normal TSH.
• Liver dysfunction: Much of the systemic T4-to-T3 conversion occurs in the liver. Hepatic impairment, including non-alcoholic fatty liver disease, reduces conversion capacity.
• Certain medications: Beta blockers, amiodarone, glucocorticoids, and some contrast agents impair T4-to-T3 conversion.

When Free T3 is low-normal (below 3.0 pg/mL) despite a normal TSH, the workup should assess selenium status, ferritin, cortisol, and liver function before assuming the thyroid itself is the problem.

Thyroid Function and Specific Longevity Pathways

Beyond its metabolic role, thyroid function intersects several aging pathways that are central to longevity medicine.

Cardiovascular health: Thyroid hormone directly regulates cardiac contractility, heart rate, systemic vascular resistance, and cholesterol metabolism. Subclinical hypothyroidism raises LDL cholesterol — sometimes by 20–30 mg/dL — and reduces cardiac output and arterial compliance. Meta-analyses have found that TSH above 4.5 mIU/L is associated with a 20–65% increased risk of coronary heart disease events, and that TSH in the 2.5–4.5 range (technically "normal") is associated with a detectable but smaller increase in risk. Conversely, overt hyperthyroidism dramatically increases atrial fibrillation risk and causes cardiac hypertrophy.

Cognitive function: T3 is required for myelination, synaptic plasticity, and neurotransmitter metabolism. Both hypothyroid and hyperthyroid states impair cognitive performance, with hypothyroidism particularly affecting memory, processing speed, and executive function. Population studies suggest that TSH in the 1–2 mIU/L range is associated with better cognitive aging trajectories than either lower or higher values.

Body composition: Thyroid hormone regulates basal metabolic rate, thermogenesis, and fat oxidation. Subclinical hypothyroidism is consistently associated with weight gain, increased visceral fat, and difficulty losing weight despite appropriate caloric restriction. The metabolic slowdown can be 10–15% below optimal even at borderline TSH levels.

Bone health: Thyroid hormones regulate bone remodeling. Overt hyperthyroidism accelerates bone turnover and increases fracture risk. Subclinical hypothyroidism has a more complex relationship with bone — generally protective against bone loss in older adults, but associated with reduced bone quality in some contexts. The relationship between thyroid function and bone underscores the importance of the optimal range, not just "not hypothyroid."

How to Test Thyroid Function

A complete thyroid assessment for longevity purposes requires more than the TSH that most annual physicals include. The minimal useful panel is TSH + Free T4 + Free T3. Adding thyroid antibodies (TPO-Ab and TgAb) provides the complete picture needed to detect Hashimoto's before it impairs function. Reverse T3 is optional but useful if conversion issues are suspected.

Through a longevity testing service: InsideTracker includes the full thyroid panel — TSH, Free T4, Free T3, and both antibodies — alongside metabolic, hormonal, and cardiovascular markers that provide essential context. This is the highest-value approach for anyone doing a comprehensive longevity baseline for the first time.

À la carte through Ulta Lab Tests: A complete thyroid panel (TSH + Free T3 + Free T4 + TPO-Ab + TgAb) is available without a doctor's visit for $50–80. This is the most cost-effective option for targeted retesting after a treatment change or dietary intervention.

Through your physician: Most physicians will order TSH and possibly Free T4 at an annual physical, but Free T3 and antibody testing often require a specific request. If you have unexplained symptoms consistent with thyroid dysfunction, it is worth asking for the complete panel explicitly.

Testing frequency depends on your baseline. If all thyroid markers are in the optimal range and you are antibody-negative, annual retesting as part of a comprehensive panel is appropriate. If you are antibody-positive but TSH is normal (euthyroid Hashimoto's), retesting TSH and Free T4 every 6–12 months is reasonable to catch any functional change early. If you are being treated for hypothyroidism, retest 6–8 weeks after any dose change.

Sources

1. Baumgartner C, et al. "Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation." Circulation, 2017. PubMed →
2. Razvi S, et al. "The Beneficial Effect of L-Thyroxine on Cardiovascular Risk Factors, Endothelial Function, and Quality of Life in Subclinical Hypothyroidism." Journal of Clinical Endocrinology & Metabolism, 2007. PubMed →
3. Stott DJ, et al. "Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism." New England Journal of Medicine, 2017. PubMed →